Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.7380
-0.0006-0.08%
Post-market: 0.74000.0020+0.27%19:55 EDT
Volume:2.82M
Turnover:2.13M
Market Cap:88.28M
PE:-0.38
High:0.7956
Open:0.7632
Low:0.7266
Close:0.7386
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
Loading ...

Invivyd announces manuscript preprint conveying data from CANOPY Phase 3 trial

TIPRANKS
·
12 Nov 2024

Invivyd Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
12 Nov 2024

Invivyd Inc - Canopy Trial Shows Strong Protection by Pemivibart in Immunocompetent Cohort

THOMSON REUTERS
·
12 Nov 2024

Invivyd Inc - Canopy Data Reconfirm High Risk Reduction in Immunocompetent Participants

THOMSON REUTERS
·
12 Nov 2024

Invivyd Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

GlobeNewswire
·
06 Nov 2024

Invivyd Initiated at Buy by EF Hutton

Dow Jones
·
30 Oct 2024

Invivyd Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Oct 2024

Invivyd Shares Fall After Revenue Guidance Withdrawal

MT Newswires Live
·
29 Oct 2024

BRIEF-Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, And Targets Near-Term Profitability

Reuters
·
29 Oct 2024

BRIEF-Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months Of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Reuters
·
29 Oct 2024

Invivyd announces 12-month exploratory data from CANOPY Phase 3 trial

TIPRANKS
·
29 Oct 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months of Follow-up, With No Additional Doses, in Immunocompetent Participants

THOMSON REUTERS
·
29 Oct 2024

Invivyd Inc: Targets Near-Term (1H 2025) Profitability With Existing Cash and Cash Equivalents

THOMSON REUTERS
·
29 Oct 2024

Invivyd Inc: Preliminary Q3 2024 Pemgarda™ (Pemivibart) Net Product Revenue of $9.3 Mln

THOMSON REUTERS
·
29 Oct 2024

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

THOMSON REUTERS
·
29 Oct 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."